Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes
Operating loss carry-forward	161,859,000		161,859,000		$ 156,586,000
Federal And State [Member]
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes	$ 0	$ 0	$ 0	$ 0

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.